All contributors
Onconephrology contributor
Leung, Nelson
Primarily MGRS & paraprotein kidney disease#1 of 47 recognizedHonor roll
- #1 in MGRS & paraprotein kidney disease
- #1 in Myeloma cast nephropathy
173
Clinical papers
8,809
Citations (iCite)
25 / 48
First / senior author
2004–2026
Active years
Output over time
Clinical corpus papers per year — peak 16 in 2020.
- 2004: 1 paper
- 2005: 4 papers
- 2007: 2 papers
- 2008: 1 paper
- 2009: 3 papers
- 2010: 7 papers
- 2011: 2 papers
- 2012: 14 papers
- 2013: 7 papers
- 2014: 4 papers
- 2015: 11 papers
- 2016: 8 papers
- 2017: 6 papers
- 2018: 11 papers
- 2019: 11 papers
- 2020: 16 papers
- 2021: 13 papers
- 2022: 8 papers
- 2023: 10 papers
- 2024: 13 papers
- 2025: 14 papers
- 2026: 7 papers
20042026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
MGRS & paraprotein kidney disease137
Myeloma cast nephropathy91
Anticancer drug nephrotoxicity19
Onco-nephrology (general)5
Cellular therapy renal effects4
Tumor lysis & electrolytes4
Checkpoint-inhibitor kidney injury3
Anti-VEGF / TKI renal effects2
Frequent collaborators
Other recognized contributors who most often share corpus papers with Leung (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Leung among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.